Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: Insights from the REVEAL Registry-Reference-Cited by-同舟云学术

Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: Insights from the REVEAL Registry

Published:2013-11 Issue:11 Volume:32 Page:1114-1122
ISSN:1053-2498
Container-title:The Journal of Heart and Lung Transplantation
language:en
Short-container-title:The Journal of Heart and Lung Transplantation

Author:

Farber Harrison W.,Miller Dave P.,Meltzer Leslie A.,McGoon Michael D.

Publisher

Elsevier BV

Subject

Transplantation,Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,Surgery

Reference39 articles.

1. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

2. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines;Badesch;Chest,2007

3. Cellular and molecular pathobiology of pulmonary arterial hypertension;Humbert;J Am Coll Cardiol,2004

4. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry;D’Alonzo;Ann Intern Med,1991

5. Ambrisentan therapy for pulmonary arterial hypertension;Galie;J Am Coll Cardiol,2005

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study;The Clinical Respiratory Journal;2023-10-07

2. Refined risk stratification, current treatment, and new therapeutic approaches in pulmonary arterial hypertension;Herz;2023-04-21

3. Current status of diagnosis and treatment of pulmonary hypertension in Chinese tertiary hospitals: A nationwide survey;Pulmonary Circulation;2023-04

4. Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension;ERJ Open Research;2022-11-10

5. INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH);Pulmonary Circulation;2022-07